<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174759</url>
  </required_header>
  <id_info>
    <org_study_id>C_9253</org_study_id>
    <secondary_id>EudraCT #: 2004-000822-58</secondary_id>
    <nct_id>NCT00174759</nct_id>
  </id_info>
  <brief_title>CASPAR : Clopidogrel and Acetyl Salicylic Acid in Bypass Surgery for Peripheral ARterial Disease</brief_title>
  <official_title>A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To evaluate whether clopidogrel 75 mg o.d. versus placebo (on a background of ASA 75-100&#xD;
      mg/d) will lead to an increased rate of primary patency, limb salvage and survival, in&#xD;
      patients receiving a below knee bypass graft for the treatment of PAD.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
      Comparison, between the two treatment groups, of :&#xD;
&#xD;
        -  Primary patency,&#xD;
&#xD;
        -  Assisted primary patency,&#xD;
&#xD;
        -  Cardiovascular death / myocardial infarction / stroke / any amputation above the ankle.&#xD;
&#xD;
        -  Ankle Brachial Pressure Index (ABPI) changes from baseline&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1st occurrence over the duration of follow-up of : index bypass graft occlusion based on imaging procedure, or graft replacement or endovascular intervention, or amputation above the ankle of the affected limb or death</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>1st occurrence of any component of following cluster of events : index bypass graft occlusion,any revascularization procedure or amputation. Change in ABPI.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">1460</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: A patient is eligible for inclusion in the study 2-4 days after surgery&#xD;
        if all the following criteria are fulfilled:&#xD;
&#xD;
          -  Informed consent obtained;&#xD;
&#xD;
          -  Chronic background treatment with daily ASA, whatever the dose, started at least 4&#xD;
             weeks before surgery. A window of a few days without ASA before surgery is acceptable,&#xD;
             according to local practice. Post-randomization use of ASA must be between 75 and 100&#xD;
             mg/day.&#xD;
&#xD;
          -  Unilateral below knee bypass graft (i.e. the distal anastomosis is below the level of&#xD;
             the knee joint) for atherosclerotic PAD within the previous 4 days;&#xD;
&#xD;
          -  Demonstration of initial patency of the index graft by an objective measurement (e.g.&#xD;
             intra-operative Doppler scanning, flow measurement, angiography, Duplex scanning)&#xD;
             during bypass surgery, or between surgery and the time of randomization;&#xD;
&#xD;
          -  No clinical evidence of graft occlusion at time of randomization.&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
        PAD medical/surgical history&#xD;
&#xD;
          -  Onset of PAD symptoms before the age of 40 years&#xD;
&#xD;
          -  Non-atherosclerotic vascular disease (e.g. Buerger's disease, popliteal entrapment&#xD;
             syndrome)&#xD;
&#xD;
          -  Patient receiving aorto-bifemoral, iliac-femoral or crossover (femoral-femoral)&#xD;
             grafts, or undergoing peripheral transcutaneous angioplasty (PTA), with or without&#xD;
             stenting, during the same surgery.&#xD;
&#xD;
        Medical history related to bleeding risk&#xD;
&#xD;
          -  Current active bleeding at surgical site&#xD;
&#xD;
          -  Withdrawal of an epidural catheter less than 12 hours before randomization&#xD;
&#xD;
          -  Current active bleeding or increased risk of bleeding, such as severe hepatic&#xD;
             insufficiency, proliferative diabetic retinopathy, peptic ulceration, bleeding&#xD;
             diathesis or coagulopathy&#xD;
&#xD;
          -  Peptic ulceration within 12 months of randomization&#xD;
&#xD;
          -  Previous or current intracranial hemorrhage or hemorrhagic stroke, or any previous&#xD;
             stroke for which the diagnosis of hemorrhagic stroke cannot be excluded&#xD;
&#xD;
          -  Any history of severe spontaneous bleeding such as gastrointestinal bleeding, gross&#xD;
             hematuria, intraocular bleeding&#xD;
&#xD;
        Other medical conditions&#xD;
&#xD;
          -  Previous disabling stroke (severe cerebral deficit such that the patient is bedridden&#xD;
             or demented)&#xD;
&#xD;
          -  NYHA Class IV heart failure&#xD;
&#xD;
          -  Uncontrolled hypertension: Systolic Blood Pressure (SBP) &gt; 180 mm Hg, or Diastolic&#xD;
             Blood Pressure (DBP) &gt; 100 mm Hg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Sagnard</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>North Ryde</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Meyrin</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>January 10, 2011</last_update_submitted>
  <last_update_submitted_qc>January 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

